top of page
News
Chat
Analysis
Education
About
Pricing
BPIQ API
BPIQ Blog
Aug 7, 2023
1 min read
SYFOVRE (APLS) vs. IZERVAY (Astellas)
Tough month for APLS • 1st: safety issue surfaces for SYFOVRE ⇨ Retinal Vasculitis • Now: IZERVAY approved early ⇨ Good for AMD patients...
Jump start your biotech due diligence
Get started →
Our platform helps you uncover your next biotech investment opportunity
bottom of page
